Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
26 juin 2023 09h54 HE
|
Nexcella, Inc.
LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other...